贝瑞和康品牌怎么样 申请店铺

我要投票 贝瑞和康在医疗器械行业中的票数:351 更新时间:2025-06-30
贝瑞和康是哪个国家的品牌?「贝瑞和康」是 北京贝瑞和康生物技术有限公司 旗下著名品牌。该品牌发源于北京市,由创始人高扬在2010-05-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力贝瑞和康品牌出海!将品牌入驻外推网,定制贝瑞和康品牌推广信息,可以显著提高贝瑞和康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

贝瑞和康怎么样

北京贝瑞和康生物技术有限公司成立于2010年5月,是专注应用高通量基因测序技术,为临床医学疾病筛查和诊断提供整体解决方案的研发型生物科技公司。

在生物医药晋升为“国家战略性新兴产业”的行业背景下,贝瑞基因凭借自主研发的核心技术,将人类基因组测序技术实践于临床检测。在先天性遗传疾病筛查和诊断领域,贝瑞基因开发出具有全套自主知识产权的贝比安“DNA产前检测”技术(简称贝比安),实现了胎儿染色体疾病的产前检测。随后,可用于婚前孕前、产前及遗传疾病先证者的科诺安染色体疾病检测(简称科诺安)、可用于辅助生殖技术中胚胎植入前染色体数目及结构异常的科孕安胚胎植入前遗传学筛查(简称科孕安)检测相继问世,进一步丰富完善了遗传病筛查与诊断的检测技术体系。在此基础上,贝瑞和康又先后研制开发出针对胎儿染色体微缺失微重复和胎儿单基因疾病基因分型的检测技术,以期实现安全、全覆盖的临床遗传疾病筛查与诊断模式。

在向遗传病筛查与诊断领域不断深入的同时,贝瑞基因在肿瘤分子诊断领域成功推出了基于高通量测序技术的昂科益(Onconi)肿瘤分子诊断产品,涉及靶向用药检测、疗效监测、用药监测、肿瘤易感性检测、肿瘤个体化医疗检测,实现肿瘤分子检测的整体覆盖。其中以具有自主知识产权的cSMART技术为核心的肿瘤基因检测为临床开启了模式。此外,贝瑞基因在产前检测、孕前检测、遗传病检测以及肿瘤检测领域累积的数据,已构建为具有中国人群特色的基因组大数据库。通过与贝勒医学院、阿里云等机构合作,贝瑞基因未来将借助云存储与云计算平台,实现基因组数据简化的终端应用和实时共享。

至此,贝瑞基因形成了从染色体数目和结构水平、染色体微缺失微重复水平、基因水平的技术维度层层深入;从婚前、孕前、产前、新生儿、癌症的产品维度渐次覆盖;从单个个体基因组数据解读到群体基因组数据分析,再到指导性个体基因组数据解读的数字化维度逐级递进的三维立体发展结构。



Beijing Beirui Hekang Biotechnology Co., Ltd. was founded in May 2010. It is a R & D biotechnology company that focuses on the application of high-throughput gene sequencing technology to provide overall solutions for clinical medical disease screening and diagnosis. Under the background of the promotion of biomedical industry to "national strategic emerging industry", berry gene, relying on the core technology of independent research and development, practices the human genome sequencing technology in clinical detection. In the field of screening and diagnosis of congenital genetic diseases, Berea gene has developed a complete set of bebian "DNA prenatal testing" technology (bebian for short) with independent intellectual property rights, which realizes the prenatal testing of fetal chromosomal diseases. Subsequently, konoan chromosomal disease detection (konoan for short) which can be used in premarital pregnancy, prenatal and genetic disease proband, and konoan genetic screening (konoan for short) which can be used in the number and structure of pre implantation chromosomes in the assisted reproductive technology, have come out successively, further enriching and improving the detection technology system of genetic disease screening and diagnosis 。 On this basis, berry and Kang have developed the detection technology for fetal chromosome microdeletion and microduplication and fetal single gene disease genotyping, in order to achieve a safe and full coverage of clinical genetic disease screening and diagnosis mode. In the field of genetic disease screening and diagnosis, berry gene has successfully launched onconi tumor molecular diagnosis products based on high-throughput sequencing technology in the field of tumor molecular diagnosis, involving targeted drug testing, efficacy monitoring, drug monitoring, tumor susceptibility testing, tumor individualized medical testing, to achieve the overall coverage of tumor molecular testing. Among them, the tumor gene detection, which is based on the smart technology with independent intellectual property rights, has opened a model for clinical practice. In addition, the data accumulated in the fields of prenatal test, pre pregnancy test, genetic disease test and tumor test of berry gene have been constructed into a large genome database with Chinese characteristics. Through cooperation with Baylor Medical College, Alibaba cloud and other institutions, Bayley gene will use cloud storage and cloud computing platform to realize terminal application and real-time sharing of genome data simplification in the future. So far, berry gene has formed a digital dimension from chromosome number and structure level, chromosome microdeletion and microduplication level, gene level; from premarital, pre pregnancy, prenatal, newborn, cancer product dimensions gradually covered; from single individual genome data interpretation to group genome data analysis to guiding individual genome data interpretation The three-dimensional development structure of degree progressive.

本文链接: https://brand.waitui.com/b653685ec.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

普祥健康申请在香港IPO

36氪获悉,港交所文件显示,普祥健康已向香港交易所提交IPO文件,已委任申万宏源证券(香港)有限公司及农银国际融资有限公司作为整体协调人。

37分钟前

美联储7月维持利率不变的概率为81.9%

据CME“美联储观察”:美联储7月维持利率不变的概率为81.9%,降息25个基点的概率为18.1%。美联储9月维持利率不变的概率为7.5%,累计降息25个基点的概率为76%,累计降息50个基点的概率为16.4%。(财联社)

37分钟前

特朗普称不打算延长7月9日关税期限

唐纳德・特朗普总统表示,他认为无需延长 7 月 9 日的贸易期限,各国需在此期限前与美国达成协议,以避免被加征更高关祱。“我认为我不需要延长,” 他在周五录制的《福克斯新闻周日早间期货》节目中接受玛丽亚・巴蒂罗莫采访时表示。随后他补充道,“我也可以延长,没什么大不了的。”在此之前,特朗普周五曾表示,政府可以对这一期限 “为所欲为”,包括延长或缩短。(新浪财经)

37分钟前

创新药主题基金有望拿下半程冠军

今年上半年接近收官,大举布局创新药赛道的汇添富香港优势精选基金业绩领跑,有望拿下公募半程冠军。今年上半年,创新药、人形机器人、北交所、新消费等热点轮番演绎,不断引爆行情,相关主题基金轮番抢先,均取得不错的投资回报。目前,配置创新药板块的基金业绩表现最为突出,霸屏公募基金业绩榜。(证券时报)

37分钟前

欧洲电力拍卖:北欧日前电价飙升 1846%

北欧电力交易所(Nord Pool)数据显示,北欧日前拍卖电价从前一日的0.79欧元/兆瓦时飙升1846%至15.37欧元/兆瓦时。德国电力价格在欧洲电力交易所(Epex Spot)上涨89%至102.42欧元/兆瓦时,创5月7日以来新高。(新浪财经)

37分钟前

本页详细列出关于贝瑞和康的品牌信息,含品牌所属公司介绍,贝瑞和康所处行业的品牌地位及优势。
咨询